Na that's the other ongoing CORE-NK cell trial in AML.
The blood cancer patients being enrolled in this trial must have failed at least one line of chemo.
But even so, there are other companies (even ASX listed) who are achieving CRs in relapsed/refractory AML. So we need to prove to have the highest rate of CRs and/or best durability to stand out from the crowd.
And that could take a long time at this rate.
Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |